Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition (SOFIA)
SOFIA: Evaluation of the Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
The SOFIA study evaluates a web-based health application for people living with one or more chronic conditions. The study aims to find out whether the SOFIA application is useful, easy to use, and used over time by participants.
The SOFIA application offers tools to support the day-to-day management of health: lifestyle challenges, health data entry and personal tracking (e.g., blood pressure, weight), medication tracking for people using pochettes-doses (pharmacy-prepared unit-dose packets), and an AI conversational assistant providing general health information. The application does not make diagnoses, give personalized medical advice, or recommend treatment. It complements usual medical care but does not replace it.
The study first enrolls people with hypertension, then, subject to ethics committee approval, people with type 2 diabetes and obesity.
Participation takes place entirely online, through the SOFIA application, accessible from a web browser (smartphone, tablet, or computer). There are no in-person visits. Participants use the application freely, at their own pace, until the end of the study. Short questionnaires (most take 1 to 3 minutes) are offered in the application during the study, and a final questionnaire (about 20 minutes) at the end.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Regulatory classification: Other Clinical Trial according to the Swiss Ordinance on Clinical Trials (ClinO, Chapter 4), Risk Category A.
Deployment model: All application users are study participants; the digital informed consent also serves as the terms of use. Enrolment is rolling from application launch and opens by condition as its content is integrated, starting with hypertension.
Data collection: Usage data (sessions, feature use, AI interactions, scan events) are collected server-side. Validated instruments are delivered individually within the application on a rotating micro-assessment schedule, with a final assessment administering all instruments simultaneously.
Safety: Adverse events can be reported at any time within the application. An urgency classifier triggers the display of emergency numbers (144 / 143) when needed.
Statistical analysis: Acceptability is tested formally (one-sided α = 0.025, mixed-effects model). Retention is evaluated descriptively, with Kaplan-Meier analysis as supportive analysis. Secondary endpoints are analyzed with mixed-effects models or generalized estimating equations. Sensitivity analyses include multiple imputation, a per-protocol set, and tipping-point analyses. Sex-disaggregated analyses are planned across all endpoints.
Data protection: Data are coded, hosted in Switzerland, and encrypted (AES-256 GCM).
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Geneva, Suisse, 1205
- Geneva University Hospitals (HUG), Division of Primary Care Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 18 years or older
- Resident or worker in the canton of Geneva
- Access to a device with a web browser and internet connection (smartphone, tablet, or computer)
- Ability to read and understand French sufficiently to use the application and complete study questionnaires
- Willing and able to comply with the study procedures
- Digital informed consent (e-consent) provided
- Self-reported diagnosis of hypertension
Exclusion Criteria:
- Current participation in another interventional clinical trial
- Inability to provide digital informed consent
- Participation in the SOFIA beta testing program
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SOFIA application
Participants with a self-reported diagnosis of hypertension using the SOFIA application. |
AI-assisted health application accessible on any device with a web browser (smartphone, tablet, or computer), comprising: (1) gamified lifestyle challenges; (2) health data entry and personal tracking; (3) medication tracking via pochettes-doses data matrix scanning; (4) an AI conversational assistant providing general, evidence-based health information. A complement to, not a replacement for, usual medical care. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
User Retention: Proportion of Participants With Sustained Inactivity (Attrition)
Délai: From registration up to 13 months
|
Attrition (proportion of participants), with sustained inactivity defined as no session for 90 consecutive days. Success criterion: attrition <20%. |
From registration up to 13 months
|
|
Acceptability: French System Usability Scale (F-SUS) Score
Délai: Approximately every 90 days from registration, up to 13 months
|
Marginal mean French System Usability Scale (F-SUS; 10 items, composite score 0-100) across administrations. Success criterion: >68. |
Approximately every 90 days from registration, up to 13 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Satisfaction and Perceived Utility: Item Scores
Délai: Approximately every 90 days from registration, up to 13 months
|
Item-level distributions across administrations (two custom items, 5-point Likert scale). |
Approximately every 90 days from registration, up to 13 months
|
|
Willingness to Recommend: Net Promoter Score (NPS)
Délai: Approximately every 90 days from registration, up to 13 months
|
Net Promoter Score (NPS; 1 item, 0-10 per respondent; NPS -100 to +100). |
Approximately every 90 days from registration, up to 13 months
|
|
Physical Activity: IPAQ-SF Score (MET-minutes/week)
Délai: Approximately every 180 days from registration, up to 13 months
|
Score trajectory across administrations (IPAQ-SF, 7 items; MET-minutes/week). |
Approximately every 180 days from registration, up to 13 months
|
|
Sleep Quality: Pittsburgh Sleep Quality Index (PSQI) Global Score
Délai: Approximately every 180 days from registration, up to 13 months
|
Score trajectory across administrations (Pittsburgh Sleep Quality Index, PSQI; global score 0-21). |
Approximately every 180 days from registration, up to 13 months
|
|
Well-Being: WHO-5 Well-Being Index Score
Délai: Approximately every 90 days from registration, up to 13 months
|
Score trajectory across administrations (WHO-5, 5 items; raw score 0-25). |
Approximately every 90 days from registration, up to 13 months
|
|
Self-Rated Health (SRH) Score
Délai: Approximately every 90 days from registration, up to 13 months
|
Score trajectory across administrations (SRH, 1 item; 1-5). |
Approximately every 90 days from registration, up to 13 months
|
|
Perceived Stress: Perceived Stress Scale (PSS-4) Score
Délai: Approximately every 90 days from registration, up to 13 months
|
Score trajectory across administrations (PSS-4, 4 items; 0-16). |
Approximately every 90 days from registration, up to 13 months
|
|
Quality of Life: Global Quality of Life Scale Score
Délai: Approximately every 90 days from registration, up to 13 months
|
Score trajectory across administrations (global quality of life scale, 1 item; 0-100). |
Approximately every 90 days from registration, up to 13 months
|
|
Self-Efficacy for Chronic Disease Management: SEM-CD 6 Score
Délai: Approximately every 180 days from registration, up to 13 months
|
Score trajectory across administrations (SEM-CD 6, 6 items; mean 1-10). |
Approximately every 180 days from registration, up to 13 months
|
|
Condition-Specific Health Knowledge: Percentage of Correct Answers (Condition Subgroups)
Délai: At registration and approximately 6 months after registration
|
Change in percentage of correct answers (health knowledge quiz). |
At registration and approximately 6 months after registration
|
|
Medication Tracking: Data Matrix Scan Confirmation Rate (Pochettes-Doses Users)
Délai: Continuously from registration, up to 13 months
|
Data matrix scan confirmation rate (proportion). |
Continuously from registration, up to 13 months
|
|
Medication-Tracking Gaps: Proportion of Missed or Mistimed Scan Events (Condition Subgroups)
Délai: Continuously from registration, up to 13 months
|
Proportion of missed or mistimed scan events among actively engaged pochettes-doses users. |
Continuously from registration, up to 13 months
|
|
Self-Reported Medication Adherence: Visual Analogue Scale (VAS) Score (Condition Subgroups)
Délai: Approximately every 90 days from registration, up to 13 months
|
Score trajectory across administrations (visual analogue scale, 1 item; 0-100). |
Approximately every 90 days from registration, up to 13 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Mayssam Nehme, MD, Geneva University Hospitals (HUG)
- Chercheur principal: Idris Guessous, MD, PhD, Geneva University Hospitals (HUG)
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Troubles nutritionnels
- Attributs de la maladie
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Diabète sucré
- En surpoids
- Conditions pathologiques, signes et symptômes
- Comportement
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- Adhésion et conformité au traitement
- Comportement de santé
- L'observance du patient
- Acceptation des soins de santé par le patient
- Obésité
- Hypertension
- Diabète sucré, Type 2
- Maladie chronique
- Adhésion aux médicaments
Autres numéros d'identification d'étude
- SOFIA-001
- BASEC 2026-01192 (Autre identifiant: Commission Cantonale d'Ethique de la Recherche (CCER), Geneva)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Participants may optionally consent to the reuse of their coded data in other research projects, subject to ethics committee approval. The scope of data, sharing modalities, and data transfer agreements have yet to be defined.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .